142 related articles for article (PubMed ID: 29668748)
21. Health outcomes of bedaquiline in the treatment of multidrug-resistant tuberculosis in selected high burden countries.
Lu X; Smare C; Kambili C; El Khoury AC; Wolfson LJ
BMC Health Serv Res; 2017 Jan; 17(1):87. PubMed ID: 28122562
[TBL] [Abstract][Full Text] [Related]
22. Costs to Health Services and the Patient of Treating Tuberculosis: A Systematic Literature Review.
Laurence YV; Griffiths UK; Vassall A
Pharmacoeconomics; 2015 Sep; 33(9):939-55. PubMed ID: 25939501
[TBL] [Abstract][Full Text] [Related]
23. Adverse events in an integrated home-based treatment program for MDR-TB and HIV in KwaZulu-Natal, South Africa.
Brust JC; Shah NS; van der Merwe TL; Bamber S; Ning Y; Heo M; Moll AP; Loveday M; Lalloo UG; Friedland GH; Gandhi NR
J Acquir Immune Defic Syndr; 2013 Apr; 62(4):436-40. PubMed ID: 23254152
[TBL] [Abstract][Full Text] [Related]
24. A systematic review of the cost and cost effectiveness of treatment for multidrug-resistant tuberculosis.
Fitzpatrick C; Floyd K
Pharmacoeconomics; 2012 Jan; 30(1):63-80. PubMed ID: 22070215
[TBL] [Abstract][Full Text] [Related]
25. Impact of adverse drug reactions on the incremental cost-effectiveness of bedaquiline for drug-resistant tuberculosis.
Schnippel K; Firnhaber C; Page-Shipp L; Sinanovic E
Int J Tuberc Lung Dis; 2018 Aug; 22(8):918-925. PubMed ID: 29991402
[TBL] [Abstract][Full Text] [Related]
26. Predictors of cure among HIV co-infected multidrug-resistant TB patients at Sizwe Tropical Disease Hospital Johannesburg, South Africa.
Umanah TA; Ncayiyana JR; Nyasulu PS
Trans R Soc Trop Med Hyg; 2015 May; 109(5):340-8. PubMed ID: 25787727
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of a nurse practitioner-physician task-sharing model for multidrug-resistant tuberculosis in South Africa.
Farley JE; Ndjeka N; Kelly AM; Whitehouse E; Lachman S; Budhathoki C; Lowensen K; Bergren E; Mabuza H; Mlandu N; van der Walt M
PLoS One; 2017; 12(8):e0182780. PubMed ID: 28783758
[TBL] [Abstract][Full Text] [Related]
28. Bedaquiline- versus injectable-containing drug-resistant tuberculosis regimens: a cost-effectiveness analysis.
Ionescu AM; Mpobela Agnarson A; Kambili C; Metz L; Kfoury J; Wang S; Williams A; Singh V; Thomas A
Expert Rev Pharmacoecon Outcomes Res; 2018 Dec; 18(6):677-689. PubMed ID: 30073886
[TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany.
Wirth D; Dass R; Hettle R
BMC Health Serv Res; 2017 Mar; 17(1):182. PubMed ID: 28270207
[TBL] [Abstract][Full Text] [Related]
30. Sharing the burden of TB/HIV? Costs and financing of public-private partnerships for tuberculosis treatment in South Africa.
Sinanovic E; Kumaranayake L
Trop Med Int Health; 2006 Sep; 11(9):1466-74. PubMed ID: 16930269
[TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness of new MDR-TB regimens: study protocol for the TB-PRACTECAL economic evaluation substudy.
Sweeney S; Gomez G; Kitson N; Sinha A; Yatskevich N; Staples S; Moodliar R; Motlhako S; Maloma M; Rassool M; Ngubane N; Ndlovu E; Nyang'wa BT
BMJ Open; 2020 Oct; 10(10):e036599. PubMed ID: 33039989
[TBL] [Abstract][Full Text] [Related]
32. Evolving rifampicin and isoniazid mono-resistance in a high multidrug-resistant and extensively drug-resistant tuberculosis region: a retrospective data analysis.
Mvelase NR; Balakrishna Y; Lutchminarain K; Mlisana K
BMJ Open; 2019 Nov; 9(11):e031663. PubMed ID: 31699736
[TBL] [Abstract][Full Text] [Related]
33. Direct costs of managing adverse drug reactions during rifampicin-resistant tuberculosis treatment in South Africa.
Schnippel K; Firnhaber C; Berhanu R; Page-Shipp L; Sinanovic E
Int J Tuberc Lung Dis; 2018 Apr; 22(4):393-398. PubMed ID: 29562986
[TBL] [Abstract][Full Text] [Related]
34. Cost of Tuberculosis Diagnosis and Treatment in Patients with HIV: A Systematic Literature Review.
de Siqueira-Filha NT; Legood R; Cavalcanti A; Santos AC
Value Health; 2018 Apr; 21(4):482-490. PubMed ID: 29680106
[TBL] [Abstract][Full Text] [Related]
35. Cost outcome analysis of decentralized care for drug-resistant tuberculosis in Johannesburg, South Africa.
van Rensburg C; Berhanu R; Hirasen K; Evans D; Rosen S; Long L
PLoS One; 2019; 14(6):e0217820. PubMed ID: 31170207
[TBL] [Abstract][Full Text] [Related]
36. Economic burden of multidrug-resistant tuberculosis: a multicenter study across Vietnamese regions.
Nam VX; Nhung NV; Hoa NB; Thuy HTT; Phuong NTM; Anh NT; Anh LTN; Trung VQ; Ha TV; Meeyai A; Thavorncharoensap M; Chaikledkaew U
Int J Tuberc Lung Dis; 2018 Aug; 22(8):912-917. PubMed ID: 29991401
[TBL] [Abstract][Full Text] [Related]
37. Converging risk factors but no association between HIV infection and multidrug-resistant tuberculosis in Kazakhstan.
van den Hof S; Tursynbayeva A; Abildaev T; Adenov M; Pak S; Bekembayeva G; Ismailov S
Int J Tuberc Lung Dis; 2013 Apr; 17(4):526-31. PubMed ID: 23485387
[TBL] [Abstract][Full Text] [Related]
38. The treatment journey of a patient with multidrug-resistant tuberculosis in South Africa: is it patient-centred?
Loveday M; Padayatchi N; Voce A; Brust J; Wallengren K
Int J Tuberc Lung Dis; 2013 Oct; 17(10 Suppl 1):56-59. PubMed ID: 24020603
[TBL] [Abstract][Full Text] [Related]
39. The evolving epidemic of drug-resistant tuberculosis among children in Cape Town, South Africa.
Seddon JA; Hesseling AC; Marais BJ; Jordaan A; Victor T; Schaaf HS
Int J Tuberc Lung Dis; 2012 Jul; 16(7):928-33. PubMed ID: 22583610
[TBL] [Abstract][Full Text] [Related]
40. Low treatment initiation rates among multidrug-resistant tuberculosis patients in Gauteng, South Africa, 2011.
Ebonwu JI; Tint KS; Ihekweazu C
Int J Tuberc Lung Dis; 2013 Aug; 17(8):1043-8. PubMed ID: 23827028
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
